Cyclogyl
Generic: CYCLOPENTOLATE HYDROCHLORIDE
Basic Information
Manufacturer
Alcon Laboratories, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
OPHTHALMIC
FDA Set ID
1d008c76-7210-4ace-90fa-7cd22762e12e
Indications & Usage
INDICATIONS AND USAGE: Cyclopentolate hydrochloride is used to produce mydriasis and cycloplegia.
Warnings
WARNINGS: FOR TOPICAL OPHTHALMIC USE ONLY .
NOT FOR INJECTION.
This preparation may cause Central Nervous System (CNS) disturbances.
This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions.
Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.
To minimize absorption, use only 1 drop of 0.5% CYCLOGYL solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes.
Observe infants closely for at least 30 minutes following instillation.
Mydriatics may produce a transient elevation of intraocular pressure.
Therefore, patients with untreated narrow angle glaucoma or anatomically narrow angles may be susceptible to angle closure following administration.
NOT FOR INJECTION.
This preparation may cause Central Nervous System (CNS) disturbances.
This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions.
Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.
To minimize absorption, use only 1 drop of 0.5% CYCLOGYL solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes.
Observe infants closely for at least 30 minutes following instillation.
Mydriatics may produce a transient elevation of intraocular pressure.
Therefore, patients with untreated narrow angle glaucoma or anatomically narrow angles may be susceptible to angle closure following administration.
Adverse Reactions
ADVERSE REACTIONS: Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae have been reported.
Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration.
These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people.
This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common.
Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages.
Severe manifestations of toxicity include coma, medullary paralysis and death.
Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration.
These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people.
This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common.
Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages.
Severe manifestations of toxicity include coma, medullary paralysis and death.